Biotech | March 09, 2022
Alvotech settles with AbbVie to secure US rights to Humira biosimilar
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
It will be the first and only global office for traditional medicine in the world
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
he financing was significantly oversubscribed with high demand from both existing and new investors.
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Through this acquisition, Ayu Health will add 1000 beds to provide localised primary and tertiary medical care for citizens of Jaipur
Adds five years of market exclusivity on approval
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
Subscribe To Our Newsletter & Stay Updated
